Nanotechnology enabled targeting of p53 deficiency in human cancer

纳米技术能够靶向人类癌症中的 p53 缺陷

基本信息

  • 批准号:
    9307738
  • 负责人:
  • 金额:
    $ 35.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-08 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract There has been little change in mortality rate of human colorectal cancer (CRC) in the past decades and the treatment options available for CRC are still very limited today. In CRC and most other human cancers, the tumor suppressor TP53 gene is frequently inactivated by mutation or deletion. Consequently, tremendous effort has been made to restore the p53 activity for cancer therapy. However, no p53-based therapy has been successfully translated into clinical cancer treatment due to the complexity of p53 signaling. Therefore, instead of restoring the p53 activity, identifying vulnerabilities conferred by TP53 deletion or mutation is a novel strategy for fighting against the p53 deficiency in human cancer. In a recent study published in Nature, we confirmed that genomic deletion of TP53 is frequently accompanied by the partial loss of neighboring essential genes and cancer cells with hemizygous TP53 deletion are remarkably vulnerable to further suppression of such neighboring essential genes. We revealed that POLR2A is such an essential gene that is often partially co-deleted with TP53 in human cancers. Such hemizygous loss of TP53/POLR2A occurs in 53, 60, and 41% of colorectal, breast, and pancreatic cancers, respectively. The POLR2A activity is specifically inhibited by α-Amanitin (Ama), a cyclic peptide of 8 amino acids found in the mushroom Amanita phalloides. We demonstrate that low doses of Ama conjugated with anti-epithelial cell adhesion molecule (EpCAM) antibody for targeting CRC can result in much enhanced tumor regression in murine models of human CRC with hemizygous deletion of POLR2A without evident systemic toxicity. However, a small fraction of CRC cells are found to be resistant to Ama in a dose-dependent manner. These drug-resistant cells are often called cancer stem-like cells (CSCs) or tumor initiating cells (TICs). A common feature of the CSCs in many cancers (e.g., CRC together with breast and pancreatic cancers) is that they overexpress the variant CD44. Our preliminary data show that the Ama-resistant CRC cells are indeed enriched with CD44, but not EpCAM. Moreover, our studies show that human breast and prostate CSCs can be effectively destroyed in vitro and in vivo using anticancer agent-laden nanoparticles that target the variant CD44 (but not the normal or non-variant CD44 on normal stem cells) with no evident systemic toxicity. Here, we hypothesize that targeted delivery of Ama and/or clinically used anticancer drugs to the variant CD44+ cancer cells with nanoparticles can overcome their drug resistance. We will test this hypothesis with two specific aims: 1, to determine the mechanisms of resistance to the Ama-based POLR2A-targted therapy of human CRCs with hemizygous loss of TP53 and 2, to determine if the combined therapy of Ama and clinically used anticancer drugs co-delivered with the variant CD44-targeting nanoparticles can overcome the drug resistance of human CRCs. It is expected that this project may result in a novel approach to targeting TP53 and could have a major impact on the treatment of colorectal and other cancers harboring TP53 deficiency.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiaoming He其他文献

Xiaoming He的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiaoming He', 18)}}的其他基金

Multiscale hydrogel biomaterials-enabled 3D modeling of cancer drug resistance
基于多尺度水凝胶生物材料的癌症耐药性 3D 建模
  • 批准号:
    10639167
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
用于靶向治疗的纳米技术和对三阴性乳腺癌治疗耐药性的基本了解
  • 批准号:
    10593921
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
用于靶向治疗的纳米技术和对三阴性乳腺癌治疗耐药性的基本了解
  • 批准号:
    10376777
  • 财政年份:
    2020
  • 资助金额:
    $ 35.91万
  • 项目类别:
Nanotechnology enabled targeting of p53 deficiency in human cancer
纳米技术能够靶向人类癌症中的 p53 缺陷
  • 批准号:
    10063652
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials
研究 microRNA-146a 活性调节生物材料异物反应的机制
  • 批准号:
    10522163
  • 财政年份:
    2017
  • 资助金额:
    $ 35.91万
  • 项目类别:
Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials
研究 microRNA-146a 活性调节生物材料异物反应的机制
  • 批准号:
    10641032
  • 财政年份:
    2017
  • 资助金额:
    $ 35.91万
  • 项目类别:
Nanotechnology enabled targeting of p53 deficiency in human cancer
纳米技术能够靶向人类癌症中的 p53 缺陷
  • 批准号:
    9193391
  • 财政年份:
    2016
  • 资助金额:
    $ 35.91万
  • 项目类别:
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification
用于低 CPA(冷冻保护剂)玻璃化冷冻的卵母细胞微囊化
  • 批准号:
    8050447
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification
用于低 CPA(冷冻保护剂)玻璃化冷冻的卵母细胞微囊化
  • 批准号:
    8325224
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification
用于低 CPA(冷冻保护剂)玻璃化冷冻的卵母细胞微囊化
  • 批准号:
    8600270
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 35.91万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了